Vir Biotechnology, Inc., was incorporated under the laws of the State of Delaware on April 7, 2016. As a clinical-stage biopharmaceutical company, VIR is committed to boosting the immune system to develop innovative therapies for serious infectious diseases and cancer. The company's approach focuses on addressing the complex mechanisms by which these threats evade immune defense. Vir's clinical development pipeline includes therapies for delta hepatitis virus and various solid tumors, and ongoing clinical programs and trials show promise for new standards of care. The company utilizes its proprietary technology platforms DAISY and PRO-XTEN to optimize antibody development. With a leadership team experienced in immunology, infectious diseases and oncology, VIR is committed to changing lives through its transformative therapies.